Bromocriptine in Dilated Cardiomyopathy Among Women of Reproductive Age

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 112 participants.

Also called NCT06250257

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 112 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06250257
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Ethiopia (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06250257. Randomized; no masking; primary purpose treatment. Start 2024-10-21 (actual); primary completion 2026-05-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Bromocriptine in Dilated Cardiomyopathy Among Women of Reproductive Age
Condition
Dilated Cardiomyopathy
Intervention (Drug)
Bromocriptine mesylate plus standard GDMT
Lead sponsor
Jimma University (class: other)
Collaborator
Ludwig-Maximilians - University of Munich (class: other)

Record details

Record id
cardio:ct-nct06250257
Content hash
fa29cc350203e52be455ceff22ad0d08a0a207877c8e8f3236a4b0f6a5133029